Showing results (101-110 of 164) with videos related to
Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2013
Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumorsPatricia LoRusso, Pasi A Jänne, Moacyr Oliveira, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid TumorsElena Gabriela Chiorean, Patricia LoRusso, Robert Matthew Strother, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid TumorsOmid Hamid, Dana B Cardin, F Stephen Hodi, et al.JCO Precision Oncology|September 16, 2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)Haider Mahdi, Navid Hafez, Deborah Doroshow, et al.The Oncologist|August 10, 2019
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF AlterationsAditya Bardia, Mrinal Gounder, Jordi Rodon, et al.Molecular Cancer Therapeutics|March 5, 2020
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid TumorsJohn H Strickler, Patricia LoRusso, Ravi Salgia, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid TumorsYoonha Choi, Neekesh V Dharia, Tomi Jun, et al.Cancer Research Communications|March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant GliomaKristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.Journal for Immunotherapy of Cancer|February 20, 2025
Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumorsJason J Luke, David J Pinato, Dejan Juric, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2019
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid TumorsAndrea Varga, Jean-Charles Soria, Antoine Hollebecque, et al.Pageof 17